Serum of sickle cell disease patients contains fetal hemoglobin silencing factors secreted from leukocytes

Tohru Ikuta, Hassan Sellak, Si Yang Liu, Nadine Odo

Research output: Contribution to journalArticle

Abstract

Background: The mechanisms that regulate fetal hemoglobin (HbF) expression in sickle cell disease (SCD) remain elusive. We previously showed that steady-state SCD patients with high HbF levels due to a γ-globin gene mutation demonstrate strong inverse correlations between HbF levels and leukocyte counts, suggesting that leukocytes play a role in regulating HbF in SCD. Materials and methods: To further investigate the role of leukocytes in HbF expression in SCD, we examined the presence of HbF silencing factors in the serum of 82 SCD patients who received hydroxyurea (HU) therapy. Results: HU-mediated HbF induction was associated with elevated total hemoglobin levels and improved red blood cell parameters, but there was no correlation with reticulocyte or platelet counts. Importantly, we again found that HU-induced HbF levels correlated with reductions in both neutrophils and lymphocytes/monocytes, indicating that these cell lineages may have a role in regulating HU-mediated HbF expression. Our in vitro studies using CD34+-derived primary erythroblasts found that patient serum preparations include HbF silencing factors that are distinct from granulocyte-macrophage colony-stimulating factor, and the activity of such factors decreases upon HU therapy. Conclusion: Together, these results demonstrate the importance of leukocyte numbers in the regulation of HbF levels for SCD patients both in steady state and under HU therapy, and that leukocytes secrete HbF silencing factors that negatively affect HbF expression in erythroidlineage cells in SCD.

Original languageEnglish (US)
Pages (from-to)95-104
Number of pages10
JournalJournal of Blood Medicine
Volume9
DOIs
StatePublished - Jun 22 2018

Fingerprint

Fetal Hemoglobin
Sickle Cell Anemia
Hydroxyurea
Leukocytes
Serum
Leukocyte Count
Reticulocyte Count
Erythroblasts
Globins
Cell Lineage
Granulocyte-Macrophage Colony-Stimulating Factor
Platelet Count
Monocytes
Hemoglobins
Neutrophils
Therapeutics
Erythrocytes
Lymphocytes
Mutation
Genes

Keywords

  • Fetal hemoglobin
  • Hydroxyurea
  • Leukocytes
  • Sickle cell disease
  • Silencing factors

ASJC Scopus subject areas

  • Hematology

Cite this

Serum of sickle cell disease patients contains fetal hemoglobin silencing factors secreted from leukocytes. / Ikuta, Tohru; Sellak, Hassan; Liu, Si Yang; Odo, Nadine.

In: Journal of Blood Medicine, Vol. 9, 22.06.2018, p. 95-104.

Research output: Contribution to journalArticle

@article{d4a6994d4f644080a95468fe97908c28,
title = "Serum of sickle cell disease patients contains fetal hemoglobin silencing factors secreted from leukocytes",
abstract = "Background: The mechanisms that regulate fetal hemoglobin (HbF) expression in sickle cell disease (SCD) remain elusive. We previously showed that steady-state SCD patients with high HbF levels due to a γ-globin gene mutation demonstrate strong inverse correlations between HbF levels and leukocyte counts, suggesting that leukocytes play a role in regulating HbF in SCD. Materials and methods: To further investigate the role of leukocytes in HbF expression in SCD, we examined the presence of HbF silencing factors in the serum of 82 SCD patients who received hydroxyurea (HU) therapy. Results: HU-mediated HbF induction was associated with elevated total hemoglobin levels and improved red blood cell parameters, but there was no correlation with reticulocyte or platelet counts. Importantly, we again found that HU-induced HbF levels correlated with reductions in both neutrophils and lymphocytes/monocytes, indicating that these cell lineages may have a role in regulating HU-mediated HbF expression. Our in vitro studies using CD34+-derived primary erythroblasts found that patient serum preparations include HbF silencing factors that are distinct from granulocyte-macrophage colony-stimulating factor, and the activity of such factors decreases upon HU therapy. Conclusion: Together, these results demonstrate the importance of leukocyte numbers in the regulation of HbF levels for SCD patients both in steady state and under HU therapy, and that leukocytes secrete HbF silencing factors that negatively affect HbF expression in erythroidlineage cells in SCD.",
keywords = "Fetal hemoglobin, Hydroxyurea, Leukocytes, Sickle cell disease, Silencing factors",
author = "Tohru Ikuta and Hassan Sellak and Liu, {Si Yang} and Nadine Odo",
year = "2018",
month = "6",
day = "22",
doi = "10.2147/JBM.S156999",
language = "English (US)",
volume = "9",
pages = "95--104",
journal = "Journal of Blood Medicine",
issn = "1179-2736",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Serum of sickle cell disease patients contains fetal hemoglobin silencing factors secreted from leukocytes

AU - Ikuta, Tohru

AU - Sellak, Hassan

AU - Liu, Si Yang

AU - Odo, Nadine

PY - 2018/6/22

Y1 - 2018/6/22

N2 - Background: The mechanisms that regulate fetal hemoglobin (HbF) expression in sickle cell disease (SCD) remain elusive. We previously showed that steady-state SCD patients with high HbF levels due to a γ-globin gene mutation demonstrate strong inverse correlations between HbF levels and leukocyte counts, suggesting that leukocytes play a role in regulating HbF in SCD. Materials and methods: To further investigate the role of leukocytes in HbF expression in SCD, we examined the presence of HbF silencing factors in the serum of 82 SCD patients who received hydroxyurea (HU) therapy. Results: HU-mediated HbF induction was associated with elevated total hemoglobin levels and improved red blood cell parameters, but there was no correlation with reticulocyte or platelet counts. Importantly, we again found that HU-induced HbF levels correlated with reductions in both neutrophils and lymphocytes/monocytes, indicating that these cell lineages may have a role in regulating HU-mediated HbF expression. Our in vitro studies using CD34+-derived primary erythroblasts found that patient serum preparations include HbF silencing factors that are distinct from granulocyte-macrophage colony-stimulating factor, and the activity of such factors decreases upon HU therapy. Conclusion: Together, these results demonstrate the importance of leukocyte numbers in the regulation of HbF levels for SCD patients both in steady state and under HU therapy, and that leukocytes secrete HbF silencing factors that negatively affect HbF expression in erythroidlineage cells in SCD.

AB - Background: The mechanisms that regulate fetal hemoglobin (HbF) expression in sickle cell disease (SCD) remain elusive. We previously showed that steady-state SCD patients with high HbF levels due to a γ-globin gene mutation demonstrate strong inverse correlations between HbF levels and leukocyte counts, suggesting that leukocytes play a role in regulating HbF in SCD. Materials and methods: To further investigate the role of leukocytes in HbF expression in SCD, we examined the presence of HbF silencing factors in the serum of 82 SCD patients who received hydroxyurea (HU) therapy. Results: HU-mediated HbF induction was associated with elevated total hemoglobin levels and improved red blood cell parameters, but there was no correlation with reticulocyte or platelet counts. Importantly, we again found that HU-induced HbF levels correlated with reductions in both neutrophils and lymphocytes/monocytes, indicating that these cell lineages may have a role in regulating HU-mediated HbF expression. Our in vitro studies using CD34+-derived primary erythroblasts found that patient serum preparations include HbF silencing factors that are distinct from granulocyte-macrophage colony-stimulating factor, and the activity of such factors decreases upon HU therapy. Conclusion: Together, these results demonstrate the importance of leukocyte numbers in the regulation of HbF levels for SCD patients both in steady state and under HU therapy, and that leukocytes secrete HbF silencing factors that negatively affect HbF expression in erythroidlineage cells in SCD.

KW - Fetal hemoglobin

KW - Hydroxyurea

KW - Leukocytes

KW - Sickle cell disease

KW - Silencing factors

UR - http://www.scopus.com/inward/record.url?scp=85049365905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049365905&partnerID=8YFLogxK

U2 - 10.2147/JBM.S156999

DO - 10.2147/JBM.S156999

M3 - Article

AN - SCOPUS:85049365905

VL - 9

SP - 95

EP - 104

JO - Journal of Blood Medicine

JF - Journal of Blood Medicine

SN - 1179-2736

ER -